RxDoctor Payments Data

Mirella Ducu, MD

Internal Medicine · West Bloomfield, MINPI 1528136066

Payments from drug & device makers

$1,495in general payments, 2019–2025

Across 81 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$220
  • Astellas Pharma US Inc$171
  • Pfizer$124
  • Otsuka America Pharmaceutical, Inc.$121
  • Novo Nordisk$96
  • GSK$93
  • plus $670 from 19 others

What the payments were for

  • Food & beverage$1,495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,495 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$169,174
Medicare patients
263
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$162,743
TrulicityDulaglutide39$38,766
MyrbetriqMirabegron65$31,773
OzempicSemaglutide25$30,009
MounjaroTirzepatide14$24,130
Rivastigmine63$14,004
RybelsusSemaglutide12$13,343
JardianceEmpagliflozin19$12,263
JanuviaSitagliptin Phosphate18$11,967
Synjardy XrEmpagliflozin/Metformin Hcl11$11,356
EntrestoSacubitril/Valsartan15$9,816
XareltoRivaroxaban18$9,134
CreonLipase/Protease/Amylase12$9,125
LinzessLinaclotide18$7,858
Fentanyl24$6,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$162,743257 claims
Lilly USA, LLCTrulicity, Mounjaro$65$62,89653 claims
Novo NordiskOzempic, Rybelsus$96$43,35337 claims
Astellas Pharma US IncMyrbetriq$171$31,77365 claims
AbbVieCreon, Linzess$220$16,98230 claims
NovartisEntresto$26$9,81615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →